Surgery – Diagnostic testing – Measuring or detecting nonradioactive constituent of body...
Reexamination Certificate
2005-04-21
2010-10-19
Nasser, Robert L (Department: 3735)
Surgery
Diagnostic testing
Measuring or detecting nonradioactive constituent of body...
C600S316000, C600S319000
Reexamination Certificate
active
07815569
ABSTRACT:
Continuous Glucose Error-Grid Analysis (CG-EGA) method, system or computer program product designed for evaluation of continuous glucose sensors providing frequent BG readings. The CG-EGA estimates the precision of such sensors/devices in terms of both BG values and temporal characteristics of BG fluctuation. The CG-EPA may account for, among other things, specifics of process characterization (location, speed and direction), and for biological limitations of the observed processes (time lags associated with interstitial sensors).
REFERENCES:
patent: 5077476 (1991-12-01), Rosenthal
patent: 6097975 (2000-08-01), Petrovsky
patent: 6181957 (2001-01-01), Lambert
patent: 6424850 (2002-07-01), Lambert
patent: 6477393 (2002-11-01), Chou
patent: 6526298 (2003-02-01), Khalil et al.
patent: 6574490 (2003-06-01), Abbink
patent: 6574501 (2003-06-01), Lambert
patent: 6633722 (2003-10-01), Kohara et al.
patent: 6654620 (2003-11-01), Wu
patent: 6675030 (2004-01-01), Ciurczak
patent: 6682933 (2004-01-01), Patel
patent: 6813519 (2004-11-01), Lebel
patent: 6853854 (2005-02-01), Proniewicz
patent: 6865408 (2005-03-01), Abbink
patent: 7025425 (2006-04-01), Kovatchev
patent: 2005/0214892 (2005-09-01), Kovatchev
patent: 2008/0287766 (2008-11-01), Rasdal et al.
patent: WO 01/72208 (2001-10-01), None
patent: WO 2004/015539 (2004-02-01), None
Chen, E. T., “Performance Evaluation of Blood Glucose Monitoring Devices”, Diabetes Technology & Therapeutics, 2003, p. 749-768, vol. 5, No. 5.
Clarke, W. L., “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose”, Diabetes Care, 1987, p. 622-628, vol. 10, No. 5.
Cox, D. J., “Accuracy of Perceiving Blood Glucose in IDDM”, Diabetes Care, 1985, p. 529-536, vol. 8, No. 6.
Cox, D. J., “The Effects of Glucose Fluctuation on Cognitive Function and QOL: The Functional Costs of Hypoglycemia and Hyperglycemia Among Adults With Type 1 or Type 2 Diabetes”, International Journal of Clinical Practice Supplement 129, 2002, p. 20-26.
Cox, D. J., “Understanding Error Grid Analysis”, Diabetes Care, 1997, p. 911-912, vol. 20, No. 6.
Derr, R., “Is HbA1c Affected by Glycemic Instability?”, Diabetes Care, 2003, p. 2728-2733, vol. 26, No. 10.
Djakoure-Platonoff, C., “Accuracy of the Continuous Glucose Monitoring System in Inpatient and Outpatient Conditions”, Diabetes & Metabolism, 2003, p. 159-162, vol. 29, Issue 2.
Feldman, B., “A Continuous Glucose Sensor Based on Wired Enzyme Technology-Results From a 3-Day Trial in Patients With Type 1 Diabetes”, Diabetes Technology & Therapeutics, 2003, p. 769-779, vol. 5, No. 5.
Gavin, J. R., “The Importance of Postprandial Hyperglycaemia”, International Journal of Clinical Practice Supplement 107, 1999, p. 14-17.
Gross, T. M., “Performance Evaluation of the MiniMed® Continuous Glucose Monitoring System During Patient Home Use”, Diabetes Technology & Therapeutics, 2000, p. 49-56, vol. 2, No. 1.
Haffner, S., “The Importance of Postprandial Hyperglycaemia in Development of Cardiovascular Disease in People With Diabetes: Point”, International Journal of Clinical Practice Supplement 123, 2001, p. 24-26.
Hanefeld, M., “Postprandial Hyperglycaemia: Noxious Effects on the Vessel Wall”, International Journal of Clinical Practice Supplement 129, 2002, p. 45-50.
Hanefeld, “Post-Prandial Hyperglycaemia and Vascular Disease”, International Journal of Clinical Practice Supplement 112, 2000, p. 13-18.
Hanefeld, M., “Risk Factors for Myocardial Infarction and Death in Newly Detected NIDDM: The Diabetes Intervention Study, 11 Year-Follow-Up”, Diabetologia, 1996, p. 1577-1583, vol. 39, No. 12.
Hanefeld, M., “The Postprandial State and the Risk of Atherosclerosis”, Diabetic Medicine, 1997, p. S6-S11, vol. 14, Issue S3.
Kapitza, C., “Continuous Glucose Monitoring: Reliable Measurements for Up to 4 Days With the SCGMI System”, Diabetes Technology & Therapeutics, 2003, p. 609-614, vol. 5, No. 4.
Kovatchev, B. P., “Assessment of Risk for Severe Hypoglycemia Among Adults With IDDM: Validation of the Low Blood Glucose Index”, Diabetes Care, 1998, p. 1870-1875, vol. 21, No. 11.
Kovatchev, B. P., “Association of Self Monitoring Blood Glucose Profiles With Glycosylated Hemoglobin in Patients with Insulin-Dependent Diabetes”, Methods in Enzymology, 2000, p. 410-417, vol. 321.
Kovatchev, B. P., “Methods for Quantifying Self-Monitoring Blood Glucose Profiles Exemplified by an Examination of Blood Glucose Patterns in Patients With Type 1 and Type 2 Diabetes”, Diabetes Technology & Therapeutics, 2002, p. 295-303, vol. 4, No. 3.
Kovatchev, B. P., “Postprandial Symptoms and Cognitive-Motor Function, and Blood Glucose in Type 2 Diabetes Mellitus”, Diabetes, Journal of the American Diabetes Association, 2003, p. A416, Supplement 1.
Kovatchev, B. P., “Risk Analysis of Blood Glucose Data: A Quantitative Approach to Optimizing the Control of Insulin Dependent Diabetes”, Journal of Theoretical Medicine, 2000, p. 1-10, vol. 3.
Lodwig, V., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics, 2003, p. 573-587, vol. 5, No. 4.
Mastrototaro, J. J., “The Minimed Continuous Glucose Monitoring System”, Diabetes Technology & Therapeutics, 2000, p. S13-S18, vol. 2, Supplement 1.
Soonthornpun, S., “Postprandial Plasma Glucose: A Good Index of Glycemic Control in Type 2 Diabetic Patients Having Near-Normal Fasting Glucose Levels”, Diabetes Research and Clinical Practice, 1999, p. 23-27, vol. 46, Issue 1.
Food and Drug Administration, “Review Criteria Assessment of Portable Blood Glucose Monitoring in Vitro Diagnostic Devices Using Glucose Oxidase, Dehydrogenase or Hexokinase Methodology”, 1997.
Diabetes Control and Complications Trial Research Group, “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long Term Complications in Insulin-Dependent Diabetes Mellitus”, The New England Journal of Medicine, 1993, p. 977-986, vol. 329, No. 14.
“Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes”, UK Prospective Diabetes Study (UKPDS) Group, The Lancet, 1998, p. 837-853, vol. 352.
Clarke William L.
Cox Daniel J.
Gonder-Frederick Linda
Kovatchev Boris P.
D'Angelo Michael
Decker Robert J.
Nasser Robert L
Novak Druce DeLuca & Quigg LLP
University of Virginia Patent Foundation
LandOfFree
Method, system and computer program product for evaluating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method, system and computer program product for evaluating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method, system and computer program product for evaluating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4238947